English

RUBIUS THERAPEUTICS, INC.

EDGAR

RUBY Annual report (10-K) · filed 2023-02-27

27 filing records in this dataset, filed from 2018-06-22 to 2023-02-27. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-32.5 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -150100000 USD Source
Operating Cash Flow: -117600000 USD Source

Free cash flow

-32.8 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -150100000 USD Source
Operating Cash Flow: -117600000 USD Source
Capital Expenditure: 5304000 USD Source
Capital Expenditure: 5038000 USD Source

Cash and cash equivalents: 14.9 million USD 2022-12-31 Source
Exact value

14900000 USD
Long-term debt including current maturities: 75 million USD 2022-09-30 Source
Exact value

75000000 USD
Shares outstanding: 90.4 million shares 2022-12-31 Source
Exact value

90387732 shares

Reported share-count change

0.36% · 324 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

90063770 shares · 2021-12-31· Source
90387732 shares · 2022-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-02-27.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 3 of 11 periods available· newest 2022-12-31
Net income: 3 of 11 periods available· newest 2022-12-31
Operating cash flow: 3 of 11 periods available· newest 2022-12-31
Capital expenditure: 3 of 11 periods available· newest 2022-12-31
Total assets: 2 of 11 periods available· newest 2022-12-31
Total liabilities: 2 of 11 periods available· newest 2022-12-31
Current assets: 2 of 11 periods available· newest 2022-12-31
Current liabilities: 2 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
Shares outstanding: 2 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2021-01-01 – 2021-12-31
Current period

USD 0

2022-01-01 – 2022-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
0 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#628595 Filing: 000170940123000005 Input fundies:Revenue: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#629852 Filing: 000170940123000005
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 16.88 million

Prior period

−USD 196.55 million

2021-01-01 – 2021-12-31
Current period

−USD 179.67 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-179666000 − -196547000 = 16881000 USD

-196547000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-179666000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Year-over-year change in Net income: 16881000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -179666000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#1434288 Filing: 000170940123000005 Input fundies:NetIncome: -196547000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#1435365 Filing: 000170940123000005
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.98 million

Prior period

−USD 145.12 million

2021-01-01 – 2021-12-31
Current period

−USD 150.1 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-150100000 − -145122000 = -4978000 USD

-145122000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-150100000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Year-over-year change in Operating cash flow: -4978000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -150100000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#944738 Filing: 000170940123000005 Input fundies:OperatingCashFlow: -145122000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#849193 Filing: 000170940123000005
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+45.4%

Prior period

USD 3.65 million

2021-01-01 – 2021-12-31
Current period

USD 5.3 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

5304000 − 3649000 = 1655000 USD

3649000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
5304000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Year-over-year change in Capital expenditure: 1655000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 5304000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#852212 Filing: 000170940123000005 Input fundies:CapitalExpenditure: 3649000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#853199 Filing: 000170940123000005
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 0
Operating costs Derived USD 178.45 million
Operating income −USD 178.45 million
Tax, interest and other Derived USD 1.22 million
Net income −USD 179.67 million

Cash

Operating cash flow −USD 150.1 million
Capital expenditure USD 5.3 million
Free cash flow Derived −USD 155.4 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	166448000 Derived	-166448000	1283000 Derived	-167731000	-133145000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -166448000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -167731000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -127648000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 5497000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	194616000 Derived	-194616000	1931000 Derived	-196547000	-148771000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -194616000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -196547000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -145122000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3649000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	178446000 Derived	-178446000	1220000 Derived	-179666000	-155404000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -178446000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -179666000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -150100000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 5304000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2022

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -166448000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -194616000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -178446000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -167731000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -196547000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -179666000 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -127648000 Open source Capital Expenditure: 5497000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -145122000 Open source Capital Expenditure: 3649000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -150100000 Open source Capital Expenditure: 5304000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -150.1M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-127648000	Operating Cash Flow: -127648000 Open source
20212021-12-31	Operating cash flow	-145122000	Operating Cash Flow: -145122000 Open source
20222022-12-31	Operating cash flow	-150100000	Operating Cash Flow: -150100000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -155.4M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-133145000	Operating Cash Flow: -127648000 Open source Capital Expenditure: 5497000 Open source
20212021-12-31	Free cash flow	-148771000	Operating Cash Flow: -145122000 Open source Capital Expenditure: 3649000 Open source
20222022-12-31	Free cash flow	-155404000	Operating Cash Flow: -150100000 Open source Capital Expenditure: 5304000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

34.4% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	No source recorded
20212021-12-31	Liabilities / assets	43.8%	Total Liabilities: 139239000 Open source Total Assets: 318021000 Open source
20222022-12-31	Liabilities / assets	34.4%	Total Liabilities: 7939000 Open source Total Assets: 23070000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.54× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Current assets / current liabilities	Not reported	No source recorded
20212021-12-31	Current assets / current liabilities	6.63×	Current Assets: 229823000 Open source Current Liabilities: 34659000 Open source
20222022-12-31	Current assets / current liabilities	2.54×	Current Assets: 20195000 Open source Current Liabilities: 7939000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 167.73 million Exact value Exact value: -167731000 USD 2020-01-01 – 2020-12-31: -167731000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RUBIUS THERAPEUTICS, INC. · 2020-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Net Income: -167731000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -167731000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#1436254 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 127.65 million Exact value Exact value: -127648000 USD 2020-01-01 – 2020-12-31: -127648000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RUBIUS THERAPEUTICS, INC. · 2020-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Operating Cash Flow: -127648000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -127648000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#850255 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	USD 5.5 million Exact value Exact value: 5497000 USD 2020-01-01 – 2020-12-31: 5497000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RUBIUS THERAPEUTICS, INC. · 2020-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Capital Expenditure: 5497000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5497000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#854186 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 133.15 million Calculation and evidence -127648000 − 5497000 USD Exact free cash flow: -133145000 USD 2020-01-01 – 2020-12-31: -127648000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 5497000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RUBIUS THERAPEUTICS, INC. · 2020-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Free cash flow: -133145000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -127648000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#850255 Filing: 000170940123000005 Input fundies:CapitalExpenditure: 5497000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#854186 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 196.55 million Exact value Exact value: -196547000 USD 2021-01-01 – 2021-12-31: -196547000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RUBIUS THERAPEUTICS, INC. · 2021-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Net Income: -196547000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -196547000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#1435365 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 145.12 million Exact value Exact value: -145122000 USD 2021-01-01 – 2021-12-31: -145122000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RUBIUS THERAPEUTICS, INC. · 2021-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Operating Cash Flow: -145122000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -145122000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#849193 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	USD 3.65 million Exact value Exact value: 3649000 USD 2021-01-01 – 2021-12-31: 3649000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RUBIUS THERAPEUTICS, INC. · 2021-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Capital Expenditure: 3649000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3649000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#853199 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 148.77 million Calculation and evidence -145122000 − 3649000 USD Exact free cash flow: -148771000 USD 2021-01-01 – 2021-12-31: -145122000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3649000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RUBIUS THERAPEUTICS, INC. · 2021-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Free cash flow: -148771000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -145122000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#849193 Filing: 000170940123000005 Input fundies:CapitalExpenditure: 3649000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#853199 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 179.67 million Exact value Exact value: -179666000 USD 2022-01-01 – 2022-12-31: -179666000 USD Inspect Net Income Open source Share or cite Citation for Net Income · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Net Income: -179666000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -179666000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#1434288 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 150.1 million Exact value Exact value: -150100000 USD 2022-01-01 – 2022-12-31: -150100000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Operating Cash Flow: -150100000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -150100000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#944738 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	USD 5.3 million Exact value Exact value: 5304000 USD 2022-01-01 – 2022-12-31: 5304000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Capital Expenditure: 5304000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5304000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#852212 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.	−USD 155.4 million Calculation and evidence -150100000 − 5304000 USD Exact free cash flow: -155404000 USD 2022-01-01 – 2022-12-31: -150100000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 5304000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RUBIUS THERAPEUTICS, INC. · 2022-12-31 RUBIUS THERAPEUTICS, INC. (edgar:1709401) Free cash flow: -155404000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:47:34Z Snapshot: cbccd2f0eb8d4454f137f4f866b07bcec6af2b35ef1042c944f97fdbcfe78ebd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1709401?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -150100000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#944738 Filing: 000170940123000005 Input fundies:CapitalExpenditure: 5304000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1709401/000170940123000005/ruby-20221231.htm#852212 Filing: 000170940123000005 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

27 filings · 2,036 latest values · 2,036 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001709401, 1709401, RUBY, edgar:1709401

Also known as RUBIUS THERAPEUTICS, INC., RUBIUS THERAPEUTICS, INC., Rubius Therapeutics, Inc.

RUBIUS THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation